2I3 Stock Overview
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Champions Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$6.55 |
| 52 Week Low | US$3.86 |
| Beta | 0.40 |
| 1 Month Change | -2.61% |
| 3 Month Change | -14.67% |
| 1 Year Change | -3.45% |
| 3 Year Change | -45.37% |
| 5 Year Change | -41.43% |
| Change since IPO | 20.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2I3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 0.3% | -0.5% |
| 1Y | -3.4% | -15.0% | 2.5% |
Return vs Industry: 2I3 exceeded the German Life Sciences industry which returned -15% over the past year.
Return vs Market: 2I3 underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 2I3 volatility | |
|---|---|
| 2I3 Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2I3's share price has been volatile over the past 3 months.
Volatility Over Time: 2I3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 230 | Ronnie Morris | www.championsoncology.com |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
Champions Oncology, Inc. Fundamentals Summary
| 2I3 fundamental statistics | |
|---|---|
| Market cap | €61.62m |
| Earnings (TTM) | -€9.06m |
| Revenue (TTM) | €45.83m |
1.3x
P/S Ratio-6.8x
P/E RatioIs 2I3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2I3 income statement (TTM) | |
|---|---|
| Revenue | US$49.22m |
| Cost of Revenue | US$29.49m |
| Gross Profit | US$19.74m |
| Other Expenses | US$29.46m |
| Earnings | -US$9.73m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 40.09% |
| Net Profit Margin | -19.76% |
| Debt/Equity Ratio | 0% |
How did 2I3 perform over the long term?
See historical performance and comparison